防己黄芪汤加味对心肾贫血综合征的临床观察  

Clinical Observation on Modified Fangjihuangqi Decoction in Treating Cardiorenal Anemia Syndrome

作　　者：孙赫[1] 邵亚凌 马辉军 

机构地区：[1]黑龙江中医药大学第一临床医学院,黑龙江 哈尔滨

出　　处：《临床医学进展》2023年第5期7490-7497,共8页Advances in Clinical Medicine

摘　　要：目的:通过临床观察研究防己黄芪汤加味对心肾贫血综合(cardiorenal anemia syndrome, CRAS)的疗效。方法:选取2021年9月~2022年9月就诊于黑龙江中医药大学附属第一医院心血管内科的患者,符合CRAS诊断且符合纳入标准的患者60例,按照随机数字表法分为对照组(30例)和治疗组(30例)。对照组:给予常规西医治疗。治疗组:给予常规西医治疗加防己黄芪汤加味治疗3个月。3个月后对两组治疗前后左心室射血分数(LVEF)、左心室收缩末内径(LVESD)、左心室舒张末内径(LVEDD)、N末端前体脑利钠肽(NT-pro BNP)水平、血肌酐(Scr)、尿素氮(BUN)、肾小球滤过率(GFR)、血红蛋白(Hb)及安全性进行比较。结果:两组患者的LVEF、LVESD、LVEDD、NT-proBNP、Scr、BUN、GFR、Hb均明显改善(P 对照组有效率(70.00%)。结论:防己黄芪汤加味对心肾贫血综合征患者的LVEF、LVESD、LVEDD、NT-proBNP、Scr、BUN、GFR、Hb均明显改善,疗效确切,安全性较高,值得临床进一步推广应用。Objective: To study the therapeutic effect of modified Fangjihuangqi Tang on cardiovascular anemia syndrome (CRAS) through clinical observation. Method: Patients who visited the Department of Cardiovascular Medicine at the First Affiliated Hospital of Heilongjiang University of Chinese Medi-cine from September 2021 to September 2022 were selected, and they met the following criteria: Sixty patients diagnosed with CRAS and meeting the inclusion criteria were randomly divided into a control group (30 cases) and a treatment group (30 cases) using a random number table method. Control group: treated with conventional Western medicine. Treatment group: Patients were treated with conventional Western medicine and modified Fangjihuangqi Tang for 3 months. Three months later, left ventricular ejection fraction (LVEF), left ventricular end systolic diameter (LVESD), left ventricular end diastolic diameter (LVEDD), N-terminal precursor brain natriuretic peptide (NT pro BNP) levels, serum creatinine (Scr), urea nitrogen (BUN), glomerular filtration rate (GFR), hemoglobin (Hb), and safety were compared between the two groups before and after treat-ment. Result: LVEF, LVESD, LVEDD, NT proBNP, Scr, BUN, GFR, Hb of both groups of patients were significantly improved (P < 0.05), and the improvement degree of the treatment group was signifi-cantly better than that of the control group (P < 0.05). The effective rate of the treatment group (93. 30%) was higher than that of the control group (70.00%). Conclusion: Modified Fangjihuangqi Tang significantly improves LVEF, LVESD, LVEDD, NT proBNP, Scr, BUN, GFR, Hb in patients with cardi-orenal anemia syndrome, with definite therapeutic effect and high safety. It is worthy of further clinical promotion and application.

关 键 词：防己黄芪汤加味 心肾贫血综合征 心功能指标 肾功能指标 疗效 

分 类 号：R54[医药卫生—心血管疾病]